O2881

Oxybutynin chloride

Name: Oxybutynin chloride
Brand: SIGMA

≥98% (TLC), Muscarinic acetylcholine receptor antagonist, powder

Synonym(s):

α-Phenylcyclohexaneglycolic acid 4-(diethylamino)-2-butynyl ester hydrochloride

Select a Size

All Photos(3)

About This Item

Empirical Formula (Hill Notation):

C₂₂H₃₁NO₃ · HCl

CAS Number:

1508-65-2

Molecular Weight:

393.95

NACRES:

NA.77

PubChem Substance ID:

57654480

UNSPSC Code:

12352200

EC Number:

216-139-7

MDL number:

MFCD00072150

Product Name

Oxybutynin chloride, ≥98% (TLC), powder

InChI key

SWIJYDAEGSIQPZ-UHFFFAOYSA-N

InChI

1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

SMILES string

Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2

assay

≥98% (TLC)

form

powder

color

white

solubility

H₂O: 50 mg/mL

originator

Johnson & Johnson

Quality Level

200

Gene Information

human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecules

Biochem/physiol Actions

Muscarinic acetylcholine receptor antagonist.

Muscarinic acetylcholine receptor antagonist; inhibits proliferation of bladder smooth muscle cells, perhaps by downregulation of growth promoting genes.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Bryophyllum pinnatum inhibits detrusor contractility in porcine bladder strips--a pharmacological study towards a new treatment option of overactive bladder.

V Schuler et al.

Phytomedicine : international journal of phytotherapy and phytopharmacology, 19(10), 947-951 (2012-07-25)

A broad spectrum of synthetic agents is available for the treatment of overactive bladder. Anti-cholinergic drugs show a poor compliance due to side effects. There is an increasing use of plant extracts in medicine. We have therefore investigated the inhibitory

Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves.

Jessica T Casey et al.

The Journal of urology, 188(4 Suppl), 1516-1520 (2012-08-23)

Abnormal bladder function following posterior urethral valve ablation can lead to deleterious effects on renal function and urinary continence. We performed a pilot study to determine if bladder dysfunction could be ameliorated by the early administration of oxybutynin. We enrolled

Clinical effectiveness of early treatment with hyperbaric oxygen therapy for severe late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in pediatric patients.

Daniele Zama et al.

Pediatric transplantation, 17(1), 86-91 (2012-12-13)

HC is a possible cause of morbidity and extended hospitalization after HSCT. Recent studies have reported the efficiency of HOT in adult patients who underwent allogeneic HSCT, but data in children are scarce. We report our single center experience with

Application drying time for oxybutynin chloride topical gel.

Diane K Newman et al.

Urologic nursing, 32(5), 265-269 (2013-03-12)

This study determined the median drying time for oxybutynin chloride topical gel (OTG) approved for treatment of overactive bladder was 3.1 minutes, Most participants reported positive perceptions of OTG attributes.

Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.

Michael H Johnson et al.

The Journal of urology, 189(4), 1268-1274 (2012-11-06)

Intravesical bacillus Calmette-Guérin is used to decrease recurrence rates of nonmuscle invasive urothelial carcinoma. Irritative urinary symptoms are a common side effect of treatment and frequently limit treatment tolerance. While anticholinergic medications may be used for symptom prophylaxis, to our

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service